Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 sept. 2024 17h00 HE | Source: Altamira Therapeutics Ltd

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked...
06 juil. 2021 09h00 HE | Source: Auris Medical AG

Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology

Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission...
21 juin 2021 08h30 HE | Source: Auris Medical AG

Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma

Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zeroSignificant reduction in tumor size, spleen size and peripheral blood lymphocyte countsResults add to extensive body of...